<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36744129</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Biomarkers in long COVID-19: A systematic review.</ArticleTitle><Pagination><StartPage>1085988</StartPage><MedlinePgn>1085988</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1085988</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2023.1085988</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Long COVID, also known as post-acute sequelae of COVID-19, refers to the constellation of long-term symptoms experienced by people suffering persistent symptoms for one or more months after SARS-CoV-2 infection. Blood biomarkers can be altered in long COVID patients; however, biomarkers associated with long COVID symptoms and their roles in disease progression remain undetermined. This study aims to systematically evaluate blood biomarkers that may act as indicators or therapeutic targets for long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A systematic literature review in PubMed, Embase, and CINAHL was performed on 18 August 2022. The search keywords long COVID-19 symptoms and biomarkers were used to filter out the eligible studies, which were then carefully evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Identified from 28 studies and representing six biological classifications, 113 biomarkers were significantly associated with long COVID: (1) Cytokine/Chemokine (38, 33.6%); (2) Biochemical markers (24, 21.2%); (3) Vascular markers (20, 17.7%); (4) Neurological markers (6, 5.3%); (5) Acute phase protein (5, 4.4%); and (6) Others (20, 17.7%). Compared with healthy control or recovered patients without long COVID symptoms, 79 biomarkers were increased, 29 were decreased, and 5 required further determination in the long COVID patients. Of these, up-regulated Interleukin 6, C-reactive protein, and tumor necrosis factor alpha might serve as the potential diagnostic biomarkers for long COVID. Moreover, long COVID patients with neurological symptoms exhibited higher levels of neurofilament light chain and glial fibrillary acidic protein whereas those with pulmonary symptoms exhibited a higher level of transforming growth factor beta.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Long COVID patients present elevated inflammatory biomarkers after initial infection. Our study found significant associations between specific biomarkers and long COVID symptoms. Further investigations are warranted to identify a core set of blood biomarkers that can be used to diagnose and manage long COVID patients in clinical practice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Lai, Liu, Manachevakul, Lee, Kuo and Bello.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Yun-Ju</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>School of Nursing, Zuckerberg College of Health Sciences, University of Massachusetts Lowell, Lowell, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shou-Hou</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manachevakul</LastName><ForeName>Sumatchara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Nursing, Zuckerberg College of Health Sciences, University of Massachusetts Lowell, Lowell, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Te-An</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Chun-Tse</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bello</LastName><ForeName>Dhimiter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Nutritional Sciences, Zuckerberg College of Health Sciences, University of Massachusetts Lowell, Lowell, MA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRP</Keyword><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">TNF-&#x3b1;</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>4</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36744129</ArticleId><ArticleId IdType="pmc">PMC9895110</ArticleId><ArticleId IdType="doi">10.3389/fmed.2023.1085988</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vodnar D, Mitrea L, Teleky B, Szabo K, Calinoiu L, Nemes S, et al. Coronavirus disease (COVID-19) caused by (SARS-CoV-2) infections: a real challenge for human gut microbiota. Front Cell Infect Microbiol. (2020) 10:575559. 10.3389/fcimb.2020.575559</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.575559</ArticleId><ArticleId IdType="pmc">PMC7756003</ArticleId><ArticleId IdType="pubmed">33363049</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney L, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. (2023) 55:101762. 10.1016/j.eclinm.2022.101762</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale K, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. (2022) 28:1706&#x2013;14. 10.1038/s41591-022-01909-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert S, Zimmermann L, Shi X, Fritsche L, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. (2022) 226:1593&#x2013;607. 10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. (2022) 11:269. 10.3390/pathogens11020269</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. (2022) 10:863&#x2013;76. 10.1016/S2213-2600(22)00126-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo P, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. (2021) 11:16144. 10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Shetty A, Delanerolle G, Zeng Y, Zhang Y, Raymont V, et al. A systematic review and meta-analysis of Long COVID symptoms. medRxiv [Preprint]. (2022). 10.1101/2022.03.08.22272091</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.08.22272091</ArticleId><ArticleId IdType="pmc">PMC10220332</ArticleId><ArticleId IdType="pubmed">37245047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sylvester S, Rusu R, Chan B, Bellows M, O&#x2019;Keefe C, Nicholson S. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin. (2022) 38:1391&#x2013;9. 10.1080/03007995.2022.2081454</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2022.2081454</ArticleId><ArticleId IdType="pubmed">35726132</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen C, Verberk I, Thijssen E, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer&#x2019;s disease: towards clinical implementation. Lancet Neurol. (2022) 21:66&#x2013;77. 10.1016/S1474-4422(21)00361-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00361-6</ArticleId><ArticleId IdType="pubmed">34838239</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ckstr&#xf6;m D, Linder J, Jakobson MS, Riklund K, Zetterberg H, Blennow K, et al. NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology. (2020) 95:e827&#x2013;38. 10.1212/WNL.0000000000010084</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010084</ArticleId><ArticleId IdType="pmc">PMC7605503</ArticleId><ArticleId IdType="pubmed">32680941</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Wang S, Kuo C, Li C, McCullough L, Bello D, et al. Prognostic serum biomarkers in cancer patients with COVID-19: a systematic review. Transl Oncol. (2022) 21:101443. 10.1016/j.tranon.2022.101443</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2022.101443</ArticleId><ArticleId IdType="pmc">PMC9057983</ArticleId><ArticleId IdType="pubmed">35523009</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzella F, Fontana M, Salvarani C, Massari M, Ruggiero P, Scelfo C, et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. (2020) 24:589. 10.1186/s13054-020-03306-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03306-6</ArticleId><ArticleId IdType="pmc">PMC7523258</ArticleId><ArticleId IdType="pubmed">32993751</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wu Z, Li J, Zhao H, Wang G. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. (2020) 55:105954. 10.1016/j.ijantimicag.2020.105954</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105954</ArticleId><ArticleId IdType="pmc">PMC7118634</ArticleId><ArticleId IdType="pubmed">32234467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauerbrei W, Taube S, McShane L, Cavenagh M, Altman D. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst. (2018) 110:803&#x2013;11. 10.1093/jnci/djy088</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djy088</ArticleId><ArticleId IdType="pmc">PMC6093349</ArticleId><ArticleId IdType="pubmed">29873743</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman D, McShane L, Sauerbrei W, Taube S. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med. (2012) 9:e1001216. 10.1371/journal.pmed.1001216</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001216</ArticleId><ArticleId IdType="pmc">PMC3362085</ArticleId><ArticleId IdType="pubmed">22675273</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:n71. 10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y, Hanneman S, Casarez R, Wang J, McCullough L. Blood biomarkers for physical recovery in ischemic stroke: a systematic review. Am J Transl Res. (2019) 11:4603&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6731415</ArticleId><ArticleId IdType="pubmed">31497186</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M, Sans H, Forman C, Nylander A, Ho H, Lu S, et al. Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. (2022) 9:e200003. 10.1212/NXI.0000000000200003</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Magdy R, Eid R, Fathy W, Abdel-Aziz M, Ibrahim R, Yehia A, et al. Characteristics and risk factors of persistent neuropathic pain in recovered COVID-19 patients. Pain Med. (2022) 23:774&#x2013;81. 10.1093/pm/pnab341</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnab341</ArticleId><ArticleId IdType="pmc">PMC8755258</ArticleId><ArticleId IdType="pubmed">34931670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M, Abdullah F, Naveed A, Ahmed S, Khan A, Hasan A. Role of circulatory miRNA-21 and associated signaling pathways in the pathogenesis of pulmonary fibrosis among individuals recovered after COVID-19 infection. Human Gene. (2022) 34:201093. 10.1016/j.humgen.2022.201093</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humgen.2022.201093</ArticleId><ArticleId IdType="pmc">PMC9329145</ArticleId><ArticleId IdType="pubmed">37521444</ArticleId></ArticleIdList></Reference><Reference><Citation>Colarusso C, Maglio A, Terlizzi M, Vitale C, Molino A, Pinto A, et al. Post-COVID-19 patients who develop lung fibrotic-like changes have lower circulating levels of IFN-&#x3b2; but higher levels of IL-1&#x3b1; and TGF-&#x3b2;. Biomedicines. (2021) 9:1931. 10.3390/biomedicines9121931</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9121931</ArticleId><ArticleId IdType="pmc">PMC8698335</ArticleId><ArticleId IdType="pubmed">34944747</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, Castro T, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. (2020) 584:463&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Alon R, Sportiello M, Kozlovski S, Kumar A, Reilly E, Zarbock A, et al. Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. Nat Rev Immunol. (2021) 21:49&#x2013;64. 10.1038/s41577-020-00470-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00470-2</ArticleId><ArticleId IdType="pmc">PMC7675406</ArticleId><ArticleId IdType="pubmed">33214719</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderbeke L, Van Mol P, Van Herck Y, De Smet F, Humblet-Baron S, Martinod K, et al. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nat Commun. (2021) 12:4117. 10.1038/s41467-021-24360-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24360-w</ArticleId><ArticleId IdType="pmc">PMC8257697</ArticleId><ArticleId IdType="pubmed">34226537</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohmwald K, G&#xe1;lvez N, Canedo-Marroqu&#xed;n G, Pizarro-Ortega M, Andrade-Parra C, G&#xf3;mez-Santander F, et al. Contribution of cytokines to tissue damage during human respiratory syncytial virus infection. Front Immunol. (2019) 10:452. 10.3389/fimmu.2019.00452</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00452</ArticleId><ArticleId IdType="pmc">PMC6431622</ArticleId><ArticleId IdType="pubmed">30936869</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. (2020) 127:104370. 10.1016/j.jcv.2020.104370</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104370</ArticleId><ArticleId IdType="pmc">PMC7194648</ArticleId><ArticleId IdType="pubmed">32344321</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanou M, Palaiodimou L, Bakola E, Smyrnis N, Papadopoulou M, Paraskevas G, et al. Neurological manifestations of long-COVID syndrome: a narrative review. Ther Adv Chronic Dis. (2022) 13:20406223221076890. 10.1177/20406223221076890</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223221076890</ArticleId><ArticleId IdType="pmc">PMC8859684</ArticleId><ArticleId IdType="pubmed">35198136</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky S, Kochanek P, Valadka A, Clark R, Chou S, Au A, et al. Blood biomarkers for detection of brain injury in COVID-19 patients. J Neurotrauma. (2021) 38:1&#x2013;43. 10.1089/neu.2020.7332</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2020.7332</ArticleId><ArticleId IdType="pmc">PMC7757533</ArticleId><ArticleId IdType="pubmed">33115334</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera J, Boutajangout A, Masurkar A, Betensky R, Ge Y, Vedvyas A, et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer&#x2019;s dementia. Alzheimers Dement. (2022) 18:899&#x2013;910. 10.1002/alz.12556</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12556</ArticleId><ArticleId IdType="pmc">PMC9011610</ArticleId><ArticleId IdType="pubmed">35023610</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher B, Spath S, Goverman J. Cytokine networks in neuroinflammation. Nat Rev Immunol. (2017) 17:49&#x2013;59. 10.1038/nri.2016.123</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.123</ArticleId><ArticleId IdType="pubmed">27916979</ArticleId></ArticleIdList></Reference><Reference><Citation>Polak S, Van Gool I, Cohen D, von der Thusen J, van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. (2020) 33:2128&#x2013;38. 10.1038/s41379-020-0603-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-020-0603-3</ArticleId><ArticleId IdType="pmc">PMC7306927</ArticleId><ArticleId IdType="pubmed">32572155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi A, Balan I, Yadav S, Matos W, Kharawala A, Gaddam M, et al. Post-COVID-19 pulmonary fibrosis. Cureus. (2022) 14:e22770. 10.7759/cureus.22770</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.22770</ArticleId><ArticleId IdType="pmc">PMC8974316</ArticleId><ArticleId IdType="pubmed">35371880</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz de Paula C, Nagashima S, Liberalesso V, Collete M, da Silva F, Oricil A, et al. COVID-19: immunohistochemical Analysis of TGF-beta signaling pathways in pulmonary fibrosis. Int J Mol Sci. (2021) 23:168. 10.3390/ijms23010168</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23010168</ArticleId><ArticleId IdType="pmc">PMC8745764</ArticleId><ArticleId IdType="pubmed">35008594</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Xiu H, Zhang S, Zhang G. The role of macrophages in the pathogenesis of ALI/ARDS. Mediators Inflamm. (2018) 2018:1264913. 10.1155/2018/1264913</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/1264913</ArticleId><ArticleId IdType="pmc">PMC5989173</ArticleId><ArticleId IdType="pubmed">29950923</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Yang D, Kong X, Wei C, LvQiu S, Wang L, et al. Case report: pirfenidone in the treatment of post-COVID-19 pulmonary fibrosis. Front Med. (2022) 9:925703. 10.3389/fmed.2022.925703</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.925703</ArticleId><ArticleId IdType="pmc">PMC9207265</ArticleId><ArticleId IdType="pubmed">35733875</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway E, Mackman N, Warren R, Wolberg A, Mosnier L, Campbell R, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. (2022) 22:639&#x2013;49. 10.1038/s41577-022-00762-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00762-9</ArticleId><ArticleId IdType="pmc">PMC9362465</ArticleId><ArticleId IdType="pubmed">35931818</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam S, Kothari H, Bosmann M. Tissue factor in COVID-19-associated coagulopathy. Thromb Res. (2022) 220:35&#x2013;47. 10.1016/j.thromres.2022.09.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.09.025</ArticleId><ArticleId IdType="pmc">PMC9525243</ArticleId><ArticleId IdType="pubmed">36265412</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas E, Ekstedt S, Piersiala K, Petro M, Karlsson A, Kagedal A, et al. Increased IL-26 associates with markers of hyperinflammation and tissue damage in patients with acute COVID-19. Front Immunol. (2022) 13:1016991. 10.3389/fimmu.2022.1016991</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1016991</ArticleId><ArticleId IdType="pmc">PMC9712219</ArticleId><ArticleId IdType="pubmed">36466824</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield K, Watson R, Schneider J, Neff C, Yamada E, Zhang M, et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog. (2022) 18:e1010359. 10.1371/journal.ppat.1010359</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010359</ArticleId><ArticleId IdType="pmc">PMC9176759</ArticleId><ArticleId IdType="pubmed">35617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Maamar M, Artime A, Pariente E, Fierro P, Ruiz Y, Gutierrez S, et al. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin. (2022) 38:901&#x2013;9. 10.1080/03007995.2022.2042991</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2022.2042991</ArticleId><ArticleId IdType="pmc">PMC8935459</ArticleId><ArticleId IdType="pubmed">35166141</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasini E, Corsetti G, Romano C, Scarabelli T, Chen-Scarabelli C, Saravolatz L, et al. Serum metabolic profile in patients with long-covid (PASC) syndrome: clinical Implications. Front Med. (2021) 8:714426. 10.3389/fmed.2021.714426</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.714426</ArticleId><ArticleId IdType="pmc">PMC8339407</ArticleId><ArticleId IdType="pubmed">34368201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrando S, Dornbush R, Lynch S, Shahar S, Klepacz L, Karmen C, et al. Neuropsychological, medical, and psychiatric findings after recovery from acute COVID-19: a cross-sectional study. J Acad Consult Liaison Psychiatry. (2022) 63:474&#x2013;84. 10.1016/j.jaclp.2022.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaclp.2022.01.003</ArticleId><ArticleId IdType="pmc">PMC8786396</ArticleId><ArticleId IdType="pubmed">35085824</ArticleId></ArticleIdList></Reference><Reference><Citation>Martone A, Tosato M, Ciciarello F, Galluzzo V, Zazzara M, Pais C, et al. Sarcopenia as potential biological substrate of long COVID-19 syndrome: prevalence, clinical features, and risk factors. J Cachexia Sarcopenia Muscle. (2022) 13:1974&#x2013;82. 10.1002/jcsm.12931</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12931</ArticleId><ArticleId IdType="pmc">PMC9349974</ArticleId><ArticleId IdType="pubmed">35698920</ArticleId></ArticleIdList></Reference><Reference><Citation>Aparisi A, Ybarra-Falcon C, Iglesias-Echeverria C, Garcia-Gomez M, Marcos-Mangas M, Valle-Penacoba G, et al. Cardio-pulmonary dysfunction evaluation in patients with persistent post-COVID-19 headache. Int J Environ Res Public Health. (2022) 19:3961. 10.3390/ijerph19073961</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19073961</ArticleId><ArticleId IdType="pmc">PMC8997887</ArticleId><ArticleId IdType="pubmed">35409644</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C, Ryan-Murua P, Rodriguez-Jimenez J, Palacios-Cena M, Arendt-Nielsen L, Torres-Macho J. Serological biomarkers at hospital admission are not related to long-term post-covid fatigue and dyspnea in COVID-19 survivors. Respiration. (2022) 101:658&#x2013;65. 10.1159/000524042</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000524042</ArticleId><ArticleId IdType="pmc">PMC9148886</ArticleId><ArticleId IdType="pubmed">35381597</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler J, Butuci M, Wong A, Kamboj A, Youngblood B. Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy. (2022) 77:1288&#x2013;91. 10.1111/all.15188</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15188</ArticleId><ArticleId IdType="pmc">PMC9299596</ArticleId><ArticleId IdType="pubmed">34820848</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Schank M, Wang L, Dang X, Cao D, Khanal S, et al. Plasma biomarkers for systemic inflammation in COVID-19 survivors. Proteomics Clin Appl. (2022) 16:e2200031. 10.1002/prca.202200031</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prca.202200031</ArticleId><ArticleId IdType="pmc">PMC9539278</ArticleId><ArticleId IdType="pubmed">35929818</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron L, Peluso M, Ding J, Kenny G, Zilberstein N, Koshy J, et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-kappaB signaling. JCI Insight. (2022) 7:e160989. 10.1172/jci.insight.164813</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.164813</ArticleId><ArticleId IdType="pmc">PMC9462470</ArticleId><ArticleId IdType="pubmed">35727635</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E, Wist J, Masuda R, Lodge S, Nitschke P, Kimhofer T, et al. Incomplete systemic recovery and metabolic phenoreversion in post-acute-phase nonhospitalized COVID-19 patients: implications for assessment of post-acute COVID-19 syndrome. J Proteome Res. (2021) 20:3315&#x2013;29. 10.1021/acs.jproteome.1c00224</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00224</ArticleId><ArticleId IdType="pubmed">34009992</ArticleId></ArticleIdList></Reference><Reference><Citation>Aparisi A, Ybarra-Falcon C, Garcia-Gomez M, Tobar J, Iglesias-Echeverria C, Jaurrieta-Largo S, et al. Exercise ventilatory inefficiency in post-COVID-19 syndrome: insights from a prospective evaluation. J Clin Med. (2021) 10:2591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8230788</ArticleId><ArticleId IdType="pubmed">34208271</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B, Guevara-Coto J, Yogendra R, Francisco E, Long E, Pise A, et al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol. (2021) 12:700782. 10.3389/fimmu.2021.700782</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.700782</ArticleId><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M, Lu S, Tang A, Durstenfeld M, Ho H, Goldberg S, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. (2021) 224:1839&#x2013;48. 10.1093/infdis/jiab490</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Tang N, Peluso M, Iyer N, Torres L, Donatelli J, et al. Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations. Cells. (2021) 10:386. 10.3390/cells10020386</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020386</ArticleId><ArticleId IdType="pmc">PMC7918597</ArticleId><ArticleId IdType="pubmed">33668514</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve D, Rojas M, Rodriguez Y, Zapata E, Ramirez-Santana C, et al. Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis. (2022) 225:2155&#x2013;62. 10.1093/infdis/jiac017</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong S, Fong S, Young B, Chan Y, Lee B, Amrun S, et al. Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. Open Forum Infect Dis. (2021) 8:ofab156. 10.1093/ofid/ofab156</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab156</ArticleId><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M, Neves P, Lima S, Lopes J, Torres M, Vallinoto I, et al. Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome. Front Cell Infect Microbiol. (2022) 12:922422. 10.3389/fcimb.2022.922422</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Ruiz J, Lomelin-Gascon J, Lira-Luna J, Perez-Fragoso A, Tapia-Conyer R, Nunez-Aguirre M, et al. FANSY POSTCOV: a composite clinical immunological predictive index for post-COVID-19 syndrome unveils distinctive features in a cohort study of mild to critical patients. Clin Transl Med. (2021) 11:e623. 10.1002/ctm2.623</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.623</ArticleId><ArticleId IdType="pmc">PMC8611773</ArticleId><ArticleId IdType="pubmed">34841707</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaskamp L, Roubal C, Uddin S, Sotzny F, Kedor C, Bauer S, et al. Serum of post-COVID-19 syndrome patients with or without ME/CFS differentially affects endothelial cell function in vitro. Cells. (2022) 11:2376. 10.3390/cells11152376</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11152376</ArticleId><ArticleId IdType="pmc">PMC9367589</ArticleId><ArticleId IdType="pubmed">35954219</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson B, Visvabharathy L, Ali S, Kang A, Patel T, Clark J, et al. Plasma biomarkers of neuropathogenesis in hospitalized patients with COVID-19 and those with postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. (2022) 9:e1151. 10.1212/NXI.0000000000001151</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001151</ArticleId><ArticleId IdType="pmc">PMC8901169</ArticleId><ArticleId IdType="pubmed">35256481</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E, et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. (2021) 19:2546&#x2013;53. 10.1111/jth.15490</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffke M, Freitag H, Rudolf G, Seifert M, Doehner W, Scherbakov N, et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med. (2022) 20:138. 10.1186/s12967-022-03346-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03346-2</ArticleId><ArticleId IdType="pmc">PMC8938726</ArticleId><ArticleId IdType="pubmed">35317812</ArticleId></ArticleIdList></Reference><Reference><Citation>Saricam E, Dursun A, Turkmen Sariyildiz G, Can N, Bozkurt E, Gonullu U, et al. Laboratory and imaging evaluation of cardiac involvement in patients with post-acute COVID-19. Int J Gen Med. (2021) 14:4977&#x2013;85. 10.2147/IJGM.S321156</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S321156</ArticleId><ArticleId IdType="pmc">PMC8412825</ArticleId><ArticleId IdType="pubmed">34511982</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>